The CHFR (Checkpoint with FHA and RING Domains) protein is a critical regulator of the cell cycle checkpoint response, particularly under conditions of mitotic stress such as microtubule disruption. It functions as an E3 ubiquitin ligase, leveraging its RING domain to mediate ubiquitination and its FHA domain to interact with phosphorylated targets. CHFR delays mitotic entry by targeting proteins like PLK1 for degradation, providing time for DNA repair or stress resolution. Dysregulation of CHFR is implicated in cancer, where promoter hypermethylation silences its expression, correlating with tumor progression, chemoresistance (e.g., to taxanes), and poor prognosis in colorectal, lung, and gastric cancers. CHFR antibodies are essential tools for detecting its expression or loss in research, enabling studies on epigenetic silencing mechanisms, biomarker potential, and therapeutic targeting. These antibodies are widely used in techniques like Western blotting, immunohistochemistry, and immunofluorescence to explore CHFR's role in maintaining genomic stability and its clinical relevance in oncology.